Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05426382
Other study ID # SK-241-NAFLD
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 20, 2022
Est. completion date April 24, 2023

Study information

Verified date April 2023
Source Sidekick Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Sidekick Health has developed a digital behavioral change program (SK-241) specifically designed for people with metabolic derangements and non-alcoholic fatty liver disease (NAFLD). The SK-241 is delivered through a mobile application and aims at improving lifestyle and health outcomes by focusing on improving diet, increasing activity levels and reducing stress. In this study, the feasibility of the newly developed digital behavioral change program (SK-241) will be evaluated in a minimum of 30 individuals with a NAFLD diagnosis. The primary aim is to explore the acceptability of the SK-241 program by its users, in addition to exploring changes in clinical outcomes and medication adherence after a 12-week intervention with 6 months follow up.


Description:

Non-alcoholic fatty liver disease (NAFLD) is an umbrella term used to describe a spectrum of liver pathology, characterized by >5% fat accumulation in the liver (steatosis), among people who drink little or no alcohol. Both genetic and lifestyle-related factors contribute to the pathogenesis of NAFLD. It is strongly associated with metabolic derangements, obesity, insulin resistance and type 2 diabetes mellitus. NAFLD is considered the liver manifestation of metabolic syndrome. NAFLD can progress from a simple steatosis to a more severe and progressive condition, referred to as non-alcoholic steatohepatitis (NASH), which is characterized by additional liver inflammation and hepatocyte injury with or without fibrosis. In general, 20% of NAFLD patients are believed to progress to NASH. Finding convenient and effective ways to incorporate lifestyle changes into daily lives of people with NAFLD and NASH is important. Sidekick Health has developed a digital behavioral change program (SK-241) for NAFLD and NASH patients consisting of an interactive mobile application. The aim of this study is primarily to assess the acceptability and feasibility of adding a digital lifestyle intervention (SK-241) to the standard of care (SoC) for NAFLD patients, by assessing participants engagement, retention and satisfaction with the SK-241 program in a minimum of 30 individuals with a NAFLD diagnosis. In addition, the clinical effectiveness of the program will be explored. A minimum of 30 individuals with a NAFLD diagnosis will be included for a 12-week intervention with 6 months follow-up.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date April 24, 2023
Est. primary completion date April 24, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 79 Years
Eligibility Inclusion Criteria: - Adults with a NAFLD diagnosis, defined as: Confirmed liver steatosis >5%, with a FibroScan CAP cutoff score of > 294 decibel (dB)/m among individuals with one or more of the following: Type 2 diabetes OR BMI>30 OR Metabolic syndrome OR Previous diagnosis of NAFLD within the last 12 months - for individuals with type 2 diabetes: Stable dose of antidiabetic medication the last 90 days before screening (metformin, glitazones, glucagon like peptide-1 (GLP-1) analogues, sodium-glucose co transporter-2 (SGLT-2) inhibitor, sulfonylurea, insulin) - Capacity to give informed consent and understands verbal and written Icelandic - Owns and knows how to operate a smartphone - Willing and able to comply with the study intervention, all scheduled visits and procedures Exclusion Criteria: - Insulin use - Known or self-reported cirrhosis - Alcohol consumption over 14 units/week for males, 7 units/week for women - Self-reported Hepatitis B (HepB), Hepatitis C (HepC), human immunodeficiency virus (HIV), or autoimmune hepatitis - Vitamin E intake of > 400 IU/day - unless stable for 12 weeks prior to baseline - Taking medications associated with liver steatosis; steroids, methotrexate, tamoxifen, amiodarone, tetracycline, valproic acid - Self-reported pregnancy - Participation in a weight loss program - History of, or any existing medical condition (e.g., ongoing cancer treatment, severe cardiopulmonary- or musculoskeletal disease, stroke, or myocardial infarction in the last 6 months) that, in the opinion of the investigator, would interfere with evaluation of the study intervention or affect the interpretation of the results of the study

Study Design


Related Conditions & MeSH terms


Intervention

Device:
A digital care solution for patients with NAFLD
A digital solution that provides remote symptom monitoring and support of healthy lifestyle choices through tasks that are made more attractive with gamification and rewards.

Locations

Country Name City State
Iceland Hjartamiðstöðin Kopavogur
Iceland Hjartavernd Kópavogur

Sponsors (3)

Lead Sponsor Collaborator
Sidekick Health Hjartamiðstöðin, Iceland, Hjartavernd, Iceland

Country where clinical trial is conducted

Iceland, 

Outcome

Type Measure Description Time frame Safety issue
Other Exploratory objective: liver steatosis Changes in Controlled Attenuation Parameter (CAP) Fibroscan score. CAP Fibroscan score is measured in decibels per meter (dB/m) and assessed at baseline, week 12 and 9 months.
CAP Fibroscan scores range from from 100 to 400 dB/m, with a lower score indicating a better outcome as it indicates less liver steatosis.
9 months
Other Exploratory objective: liver fibrosis Changes in Liver Stiffness Measurement (LSM) Fibroscan score.The LSM Fibroscan scores are measured in kilopascal (kPa) and assessed at baseline, week 12 and 9 months.
LSM FibroScan scores range from 2.5 kPa to 75 kPa. A lower scores indicates a better outcome.
9 months
Other Safety objective: Monitor the safety and any potential adverse effects of the digital solution on patients and outcomes. Incidence of adverse events (AE) and serious adverse events (SAE) reportings at week 12 and 9 months. 9 months
Primary Acceptability and feasibility of the digital program (SK-241) - retention. Assess retention by percentage of users that complete the SK-241 program at week 12. 'Complete the program' is defined as finishing 75% of the program. 12 weeks
Primary Acceptability and feasibility of the digital program (SK-241) - engagement. Assess engagement by percentage of users that are active in the SK-241 program during the 12 weeks. 'Active' is defined as visiting the application at least once per week. 12 weeks
Primary Acceptability and feasibility of the digital program (SK-241) - satisfaction. Assess satisfaction based on the scores in the 18-item mobile health (mHealth) App Usability Questionnaire at week 12.
Answers are scored on a 7-point Likert scale (ranging from 1 for "strongly disagree"to 7 "strongly agree") and total scores range from 18 to 126. The higher the score, the better the usability.
12 weeks
Secondary The feasibility of adding a digital program (SK-241) to standard of care, by exploring its effects on weightloss. Change in weight, from baseline to week 12 and month 9 9 months
Secondary The feasibility of adding a digital program (SK-241) to standard of care, by exploring its effects on HbA1c. Changes, from baseline to week 12 and month 9 in:
Hemoglobin A1c (HbA1c), expressed in millimol per mol (mmol/mol).
9 months
Secondary The feasibility of adding a digital program (SK-241) to standard of care, by exploring its effects on fasting glucose. Changes, from baseline to week 12 and month 9 in:
fasting glucose, measured in millimol per liter (mmol/L)
9 months
Secondary The feasibility of adding a digital program (SK-241) to standard of care, by exploring its effects on fasting insulin. Changes, from baseline to week 12 and month 9 in:
fasting insulin, measured in picomol per liter (pmol//L)
9 months
Secondary The feasibility of adding a digital program (SK-241) to standard of care, by exploring its effects on liver function. Changes, from baseline to week 12 and month 9, in liver enzymes in the serum:
Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Gamma- Glutamyl Transferase (GGT), all measured in international units per liter (IU/L)
9 months
Secondary The feasibility of adding a digital program (SK-241) to standard of care, by exploring its effects on cholesterol. Changes, from baseline to week 12 and month 9 in:
Total cholesterol, Low Density Lipoprotein - Cholesterol (LDL-C), High Density Lipoprotein - Cholesterol (HDL-C), and triglycerides. These are all measured in millimol per liter (mmol/L)
9 months
Secondary The feasibility of adding a digital program (SK-241) to standard of care, by exploring its effects on hs-CRP. Changes, from baseline to week 12 and month 9, in:
high-sensitivity C-reactive protein (hs-CRP), measured in milligram per liter (mg/L)
9 months
Secondary The feasibility of adding a digital program (SK-241) to standard of care, by exploring its effects on the cardiovascular risk factor blood pressure Changes, from baseline to week 12 and month 9, in:
Blood pressure in millimeters of mercury (mmHg)
9 months
Secondary The feasibility of adding a digital program (SK-241) to standard of care, by exploring its effects on the cardiovascular risk factor waist circumference. Changes, from baseline to week 12 and month 9, in:
Waist circumference in centimeters (cm)
9 months
Secondary The feasibility of adding a digital program (SK-241) to standard of care, by exploring its effects on the cardiovascular risk factor activity level. Changes, from baseline to week 12 and month 9, in:
Activity level, as assessed with an in-app step counter, and measured in number of steps
9 months
Secondary The feasibility of adding a digital program (SK-241) to standard of care, by exploring its effects on body composition. Changes in body composition (fat mass and lean mass), measured by dual-energy X-ray absorptiometry (DXA) at baseline, week 12 and 9 months.
Fat mass and lean mass are both expressed as percentage (%).
9 months
Secondary The feasibility of adding a digital program (SK-241) to standard of care, by exploring its effects on liver fat content. Changes in liver fat fraction (%) assessed by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) at baseline, week 12 and 9 months. 9 months
Secondary The feasibility of adding a digital program (SK-241) to standard of care, by assessing health related quality of life (HRQoL) Changes in self-reported scores on the EuroQuol Five Dimension - Five Level (EQ-5D-5L) health questionnaire from baseline to week 12 and month 9.
EQ-E5-5L scores range from -0.530 to 1, with higher scores indicating a better health status. A score of 1 indicates full health.
9 months
Secondary The feasibility of adding a digital program (SK-241) to standard of care, by assessing mental health. Changes in self-reported scores of the Depression, Anxiety and Stress Scale - 21 Items (DASS-21) questionnaire from baseline to week 12 and month 9.
Each question has a Likert scale of 4 options where 0 represents "did not apply to me" to 3 "applied to me very much". The scores on the subscales range from 0 to 42, and low scores indicate a better mental health status.
9 months
Secondary The feasibility of adding a digital program (SK-241) to standard of care, by assessing medication adherence. Changes in self-reported scores on the Morisky Medication adherence Scale (MMAS-8) questionnaire from baseline to week 12 and month 9. The MMAS-8 is an 8-item structured, self-reported medication adherenece measure.
Scores on the MMAS-8 range from 0-8, with 0 reflecting high adherence, 1-2 medium adherence and 3-8 low adherence.
9 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02248311 - "Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population N/A
Completed NCT01277237 - The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease Phase 3
Active, not recruiting NCT04442620 - Prevention and Reversion of NAFLD in Obese Patients With Metabolic Syndrome by Mediterranean Diet and Physical Activity N/A
Completed NCT01999101 - Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Phase 2
Completed NCT01327443 - Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease N/A
Active, not recruiting NCT01482065 - The Sleep, Liver Evaluation and Effective Pressure Study N/A
Completed NCT03135873 - Mastiha Treatment for Obese With NAFLD Diagnosis N/A
Completed NCT02686476 - Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes N/A
Completed NCT02820285 - Characterization of Immune Semaphorin in Non Alcoholic Fatty Liver Disease and NASH N/A
Completed NCT01556113 - Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease N/A
Recruiting NCT06080386 - UDFF Performance Evaluation ((Ultrason Derived Fat Fraction)
Terminated NCT02134522 - The Role of Obstructive Sleep Apnea in Children With Fatty Liver Disease N/A
Completed NCT01553500 - Glucomannan Effects on Children With Non-alcoholic Fatty Liver Disease Phase 2
Completed NCT03300661 - Non Alcoholic Fatty Liver Disease: Nutritional Epidemiology and Lifestyle Medicine N/A
Not yet recruiting NCT02178839 - The Effect of Oral β- Glucan Supplement on Appetite and Insulin Resistance in Non Alcoholic Fatty Liver Disease N/A
Recruiting NCT02038387 - Prospective Clinical Study of the Role of the Immune Response, in Relation to Diet, in Patients Affected by Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD) N/A
Completed NCT01874249 - Non Invasive Assessment of Liver Fibrosis in Fatty Liver Disease N/A
Completed NCT01634048 - The Effect of Protein-enriched Diet on Body Composition and Appetite N/A
Completed NCT01966627 - Genetics of Fatty Liver Disease in Children N/A
Terminated NCT01842282 - Amlexanox for Type 2 Diabetes and Obesity Phase 2